| Title |
Advances in the treatment of newly diagnosed glioblastoma
|
|---|---|
| Published in |
BMC Medicine, December 2015
|
| DOI | 10.1186/s12916-015-0536-8 |
| Pubmed ID | |
| Authors |
Brett J. Theeler, Mark R. Gilbert |
| Abstract |
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| United Kingdom | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Netherlands | 1 | 1% |
| Sweden | 1 | 1% |
| Unknown | 86 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 13 | 15% |
| Student > Bachelor | 13 | 15% |
| Student > Ph. D. Student | 11 | 12% |
| Student > Master | 9 | 10% |
| Researcher | 8 | 9% |
| Other | 18 | 20% |
| Unknown | 17 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 33% |
| Neuroscience | 10 | 11% |
| Biochemistry, Genetics and Molecular Biology | 10 | 11% |
| Agricultural and Biological Sciences | 10 | 11% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 8% |
| Unknown | 21 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 May 2016.
All research outputs
#12,939,625
of 22,835,198 outputs
Outputs from BMC Medicine
#2,726
of 3,430 outputs
Outputs of similar age
#177,173
of 388,741 outputs
Outputs of similar age from BMC Medicine
#39
of 45 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,430 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.6. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,741 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.